Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Aberrant nigral diffusion in Parkinson's disease : A longitudinal diffusion tensor imaging study. / Loane, Clare; Politis, Marios; Kefalopoulou, Zinovia; Valle-Guzman, Natalie; Paul, Gesine; Widner, Håkan; Foltynie, Thomas; Barker, Roger A; Piccini, Paola.

I: Movement Disorders, Vol. 31, Nr. 7, 07.2016, s. 1020-6.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Loane, C, Politis, M, Kefalopoulou, Z, Valle-Guzman, N, Paul, G, Widner, H, Foltynie, T, Barker, RA & Piccini, P 2016, 'Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study', Movement Disorders, vol. 31, nr. 7, s. 1020-6. https://doi.org/10.1002/mds.26606

APA

CBE

Loane C, Politis M, Kefalopoulou Z, Valle-Guzman N, Paul G, Widner H, Foltynie T, Barker RA, Piccini P. 2016. Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. Movement Disorders. 31(7):1020-6. https://doi.org/10.1002/mds.26606

MLA

Vancouver

Author

Loane, Clare ; Politis, Marios ; Kefalopoulou, Zinovia ; Valle-Guzman, Natalie ; Paul, Gesine ; Widner, Håkan ; Foltynie, Thomas ; Barker, Roger A ; Piccini, Paola. / Aberrant nigral diffusion in Parkinson's disease : A longitudinal diffusion tensor imaging study. I: Movement Disorders. 2016 ; Vol. 31, Nr. 7. s. 1020-6.

RIS

TY - JOUR

T1 - Aberrant nigral diffusion in Parkinson's disease

T2 - A longitudinal diffusion tensor imaging study

AU - Loane, Clare

AU - Politis, Marios

AU - Kefalopoulou, Zinovia

AU - Valle-Guzman, Natalie

AU - Paul, Gesine

AU - Widner, Håkan

AU - Foltynie, Thomas

AU - Barker, Roger A

AU - Piccini, Paola

N1 - © 2016 International Parkinson and Movement Disorder Society.

PY - 2016/7

Y1 - 2016/7

N2 - BACKGROUND: Measuring microstructure alterations with diffusion tensor imaging in PD is potentially a valuable tool to use as a biomarker for early diagnosis and to track disease progression. Previous studies have reported a specific decrease of nigral fractional anisotropy in PD. However, to date the effect of disease progression on nigral or striatal diffusion indices has not been fully explored.METHODS: We have conducted a cross-sectional and longitudinal diffusion tensor imaging study in 18 early stage, treated PD patients and 14 age-matched controls. PD patients were scanned on 2 occasions OFF medication, 19.3 months apart (standard deviation = 3.1 months). Longitudinal change of regional nigral and striatal measures of fractional anisotropy and mean diffusivity were calculated using a region-of-interest approach.RESULTS: Region-of-interest analysis demonstrated that at baseline, PD patients and controls did not differ in regard to diffusion indices in any region assessed. A significant difference of nigral fractional anisotropy and mean diffusivity between controls and PD patients at follow-up was detected and confirmed with longitudinal analysis within PD patients. Alterations in striatal regions were not detected in either group or over time.CONCLUSION: Our findings indicate that nigral diffusion measure may be a valuable measure of disease progression. In the future, larger longitudinal studies will confirm whether diffusion indices may serve as sensitive and clinically meaningful measures of disease progression in PD. © 2016 International Parkinson and Movement Disorder Society.

AB - BACKGROUND: Measuring microstructure alterations with diffusion tensor imaging in PD is potentially a valuable tool to use as a biomarker for early diagnosis and to track disease progression. Previous studies have reported a specific decrease of nigral fractional anisotropy in PD. However, to date the effect of disease progression on nigral or striatal diffusion indices has not been fully explored.METHODS: We have conducted a cross-sectional and longitudinal diffusion tensor imaging study in 18 early stage, treated PD patients and 14 age-matched controls. PD patients were scanned on 2 occasions OFF medication, 19.3 months apart (standard deviation = 3.1 months). Longitudinal change of regional nigral and striatal measures of fractional anisotropy and mean diffusivity were calculated using a region-of-interest approach.RESULTS: Region-of-interest analysis demonstrated that at baseline, PD patients and controls did not differ in regard to diffusion indices in any region assessed. A significant difference of nigral fractional anisotropy and mean diffusivity between controls and PD patients at follow-up was detected and confirmed with longitudinal analysis within PD patients. Alterations in striatal regions were not detected in either group or over time.CONCLUSION: Our findings indicate that nigral diffusion measure may be a valuable measure of disease progression. In the future, larger longitudinal studies will confirm whether diffusion indices may serve as sensitive and clinically meaningful measures of disease progression in PD. © 2016 International Parkinson and Movement Disorder Society.

KW - Journal Article

U2 - 10.1002/mds.26606

DO - 10.1002/mds.26606

M3 - Article

VL - 31

SP - 1020

EP - 1026

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 7

ER -